$SEER earnings report

Seer reports Q3 2026 revenue of $4.0 million, down 3% year over year, net loss of $13.7 million, and cuts FY2026 revenue guidance to $13.5 million to $14.5 million from $16 million to $18 million. AlphAI read Seer's Q3 FY2026 filing as weak. 2 quarters are on record below.

Q3 FY2026

AlphAI · Earnings readSEER · Q3 2026 · ended 2026-09-30

Seer reports Q3 2026 revenue of $4.0 million, down 3% year over year, net loss of $13.7 million, and cuts FY2026 revenue guidance to $13.5 million to $14.5 million from $16 million to $18 million

↓Weak quarter

Revenue fell 3% year over year and was $3.1 million in Q2 2026 (printed). The company lowered its FY2026 revenue range to $13.5 million to $14.5 million from the prior $16 million to $18 million, citing extended academic and government sales cycles. Operating expenses fell 23% and the net loss narrowed, but the nine-month free cash flow was approximately negative $34.8 million (non-GAAP).

Revenue
$3.98M
-3% y/y
Product revenue
$2,760 thousand (Q3 2026); $2.8 million per text
Gross margin · GAAP
47%
EPS · GAAP
$(0.25)
FY2026 full-year revenue outlook
$13.5 million to $14.5 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenue, Q3 2026 (three months ended Sep 30, 2026)GAAP$3.98M–-3%
Product revenue, Q3 2026GAAP$2.76M––
Service revenue, Q3 2026GAAP$1.06M––
Related party revenue, Q3 2026GAAP$90K––
Other revenue, Q3 2026GAAP$67K––
Total cost of revenue, Q3 2026GAAP$2.10M––
Gross profit, Q3 2026GAAP$1.88M––
Gross margin, Q3 2026GAAP47%––
Research and development expense, Q3 2026GAAP$6.44M––
Selling, general and administrative expense, Q3 2026GAAP$10.11M––
Total operating expenses, Q3 2026GAAP$16.55M–-23%
Stock-based compensation included in operating expenses, Q3 2026GAAP$1.2M––
Loss from operations, Q3 2026GAAP−$14.67M––
Interest income, Q3 2026GAAP$1.96M––
Loss on equity method investment, Q3 2026GAAP−$1.39M––
Total other income, Q3 2026GAAP$934K––
Loss before provision for income taxes, Q3 2026GAAP−$13.73M––
Provision for income taxes, Q3 2026GAAP$5K––
Net loss, Q3 2026GAAP−$13.74M––
Net loss per share, basic and diluted, Q3 2026GAAP$(0.25)––
Comprehensive loss, Q3 2026GAAP−$14.15M––
Total revenue, nine months ended Sep 30, 2026GAAP$9.88M––
Gross profit, nine months ended Sep 30, 2026GAAP$4.37M––
Research and development expense, nine months ended Sep 30, 2026GAAP$23.45M––
Selling, general and administrative expense, nine months ended Sep 30, 2026GAAP$29.68M––
Total operating expenses, nine months ended Sep 30, 2026GAAP$53.13M––
Loss from operations, nine months ended Sep 30, 2026GAAP−$48.76M––
Net loss, nine months ended Sep 30, 2026GAAP−$47.47M––
Net loss per share, basic and diluted, nine months ended Sep 30, 2026GAAP$(0.85)––
Net cash used in operating activities, nine months ended Sep 30, 2026otherapproximately $34.5 million––
Free cash flow, nine months ended Sep 30, 2026non-GAAPapproximately negative $34.8 million––
Net purchases of property and equipment, nine months ended Sep 30, 2026otherapproximately $311,000––
Cash, cash equivalents and investments, as of Sep 30, 2026otherapproximately $198.1 million––
Total assets, as of Sep 30, 2026GAAP$241.8M––
Total stockholders' equity, as of Sep 30, 2026GAAP$212.9M––

Segments

SegmentRevenueq/qy/y
Product revenueFiling describes product revenue as sales of Proteograph instruments and consumable kits. No driver for the change is stated.$2,760 thousand (Q3 2026); $2.8 million per text––
Service revenueNo driver stated in the filing.$1,064 thousand (Q3 2026); $1.1 million per text––
Related party revenueNo driver stated in the filing.$90 thousand (Q3 2026); $0.1 million per text––
Other revenueNo driver stated in the filing.$67 thousand (Q3 2026); approximately $67,000 per text––

FY2026 full-year revenue outlook

  • Revenue$13.5 million to $14.5 million
  • NoteFiling states the range was updated from a prior range of $16 million to $18 million.
  • NoteCompany attributes the change to continued pressure on academic and government funding, which has extended sales cycles, and to several late-stage opportunities now expected to close later than planned.

Capital returns

  • Through Sep 30, 2026, the company had repurchased approximately 13.5 million Class A common shares at a weighted average price of $1.85 per share.
  • These repurchases used approximately $25 million of the combined $50 million authorized by the Board in May 2024 and February 2026.
  • Approximately $25 million remained available under those authorizations as of the filing.
  • During Q3 2026 the company repurchased approximately 61,000 shares at a weighted-average price of $1.64 per share.
  • The company describes its capital allocation as combining investment in commercial adoption and product innovation with disciplined spending and share repurchases.

What drove it

  • Company states operating expenses decreased 23% primarily reflecting lower employee compensation expenses, including stock-based compensation.
  • Company states revenue guidance was lowered because continued pressure on academic and government funding has extended sales cycles.
  • Company states several late-stage opportunities are now expected to close later than planned.
  • Company states established customers continued to purchase consumables, including accounts with purchases across multiple consecutive quarters.
  • Company states several new large pharmaceutical customers purchased instruments and consumables this year.

Concerns

  • Q3 2026 revenue of $3,981 thousand was below the $4,121 thousand of Q3 2025.
  • FY2026 revenue guidance now ranges $13.5 million to $14.5 million, below the prior $16 million to $18 million range printed in the filing.
  • Nine-month revenue of $9,876 thousand compares with $12,377 thousand in the prior-year nine months.
  • Gross margin of 47% is printed for Q3 2026 without a prior-year comparison in the filing.
  • Free cash flow for the nine months was approximately negative $34.8 million (non-GAAP).
  • Total assets fell from $296,083 thousand at Dec 31, 2025 to $241,799 thousand at Sep 30, 2026, and equity fell from $259,307 thousand to $212,891 thousand.
  • Loss on equity method investment was $(1,392) thousand in Q3 2026 and $(5,208) thousand for the nine months.
  • Gross profit fell to $1,879 thousand from $2,110 thousand in the prior-year quarter as cost of revenue rose to $2,102 thousand from $2,011 thousand.

What to watch

  • Timing of the late-stage opportunities the company says are now expected to close later than planned.
  • Whether sample volume growth within existing customer accounts shows up in consumable revenue, as the CEO's quote describes as the focus.
  • Final determination of the U.S. International Trade Commission investigation, which the company says is pending and expected by year-end.
  • Whether the company reaches cash flow breakeven as stated in its current operating plan, given the nine-month free cash flow of approximately negative $34.8 million.
  • Remaining buyback capacity of approximately $25 million and the pace of repurchases.
  • Q4 2026 revenue needed to land within the updated $13.5 million to $14.5 million full-year range.

Balance sheet and cash flow

  • Cash and cash equivalents: $29,316 thousand as of Sep 30, 2026, versus $47,285 thousand as of Dec 31, 2025.
  • Short-term investments: $126,581 thousand as of Sep 30, 2026, versus $138,612 thousand as of Dec 31, 2025.
  • Long-term investments: $42,190 thousand as of Sep 30, 2026, versus $54,686 thousand as of Dec 31, 2025.
  • Total assets: $241,799 thousand as of Sep 30, 2026, versus $296,083 thousand as of Dec 31, 2025.
  • Total liabilities: $28,908 thousand as of Sep 30, 2026, versus $36,776 thousand as of Dec 31, 2025.
  • Total stockholders' equity: $212,891 thousand as of Sep 30, 2026, versus $259,307 thousand as of Dec 31, 2025.
  • Accounts payable: $2,583 thousand as of Sep 30, 2026, versus $5,611 thousand as of Dec 31, 2025.
  • Accumulated deficit: $(513,446) thousand as of Sep 30, 2026, versus $(465,972) thousand as of Dec 31, 2025.
  • Company states it believes it has sufficient capital to reach cash flow breakeven based on its current operating plan.

Analysis

Seer reported third-quarter 2026 revenue of $3,981 thousand, down 3% from $4,121 thousand in the year-earlier quarter and up from the $3.1 million printed for Q2 2026. Product revenue of $2,760 thousand was nearly flat against $2,756 thousand a year earlier, while service revenue rose to $1,064 thousand from $913 thousand. Related party revenue fell to $90 thousand from $300 thousand and other revenue fell to $67 thousand from $152 thousand. The company says established customers continued to buy consumables and that several new large pharmaceutical customers purchased instruments and consumables this year.

Profitability moved mainly through operating expenses. Total operating expenses were $16,546 thousand against $21,456 thousand, a decrease the company describes as 23%, which it attributes primarily to lower employee compensation, including stock-based compensation. Research and development fell to $6,439 thousand from $10,797 thousand, while SG&A moved to $10,107 thousand from $10,659 thousand. Gross profit was $1,879 thousand, or 47% of revenue as printed, against $2,110 thousand a year earlier, with cost of revenue rising to $2,102 thousand from $2,011 thousand. The net loss was $(13,738) thousand against $(18,234) thousand, and the printed net loss per share was $(0.25) against $(0.32). Interest income declined to $1,961 thousand from $2,765 thousand, which is a smaller contribution to the quarter's result.

The nine-month figures show the same pattern at a larger scale. Revenue was $9,876 thousand against $12,377 thousand, operating expenses were $53,131 thousand against $66,889 thousand, and the net loss was $(47,474) thousand against $(57,606) thousand. Net cash used in operating activities was approximately $34.5 million, and after net purchases of property and equipment of approximately $311,000, free cash flow was approximately negative $34.8 million on the company's non-GAAP definition. Cash, cash equivalents and investments were approximately $198.1 million at Sep 30, 2026. Balance sheet cash and cash equivalents were $29,316 thousand against $47,285 thousand at Dec 31, 2025, and total stockholders' equity was $212,891 thousand against $259,307 thousand.

Capital allocation included repurchases of approximately 13.5 million Class A shares at a weighted average of $1.85 per share through Sep 30, 2026, using approximately $25 million of the $50 million combined authorization. About $25 million remained available, and Q3 repurchases were approximately 61,000 shares at $1.64 weighted average. The company states it believes it has sufficient capital to reach cash flow breakeven under its current operating plan.

The most important change in the release is the full-year revenue guidance, now $13.5 million to $14.5 million against the prior $16 million to $18 million range printed in the filing. The company attributes this to continued pressure on academic and government funding, which has extended sales cycles, and to several late-stage opportunities now expected to close later than planned. The company also reports a pending ITC determination on an investigation where the investigative staff recommended the requested exclusion and cease-and-desist orders, with a final Commission decision expected by year-end. Investors will need to weigh the expense reduction and narrower loss against a lower revenue outlook and continued negative cash flow.

Management, verbatim

Our focus is to translate that differentiated value into sustained revenue growth by expanding sample volume within customer accounts and building relationships that support repeat use.

Omid Farokhzad, Chair and Chief Executive Officer

With a strong balance sheet and growing evidence of the platform's value, I remain confident in Seer's opportunity and committed to building long-term value for our shareholders.

Omid Farokhzad, Chair and Chief Executive Officer

Not in the filing

stated, not guessed
  • Prior-year and prior-quarter comparisons as percentages for product, service, related party and other revenue were not printed.
  • Prior-year gross margin was not printed; only the Q3 2026 gross margin of 47% is stated.
  • Q2 2026 detail beyond total revenue of $3.1 million was not printed.
  • Balance sheet comparisons are against Dec 31, 2025, not the prior-year quarter, and are listed in balance_sheet_cash_flow rather than as prior_year fields.
  • Prior-year nine-month operating cash flow and free cash flow were not printed.
  • Guidance for gross margin, operating expenses and tax rate was not provided.
  • Consensus estimates, analyst expectations and share price reaction were not provided in the documents.
  • Stock-based compensation for the nine-month periods was not printed.
  • Reasons for changes in other income, equity method losses, and the tax provision were not stated.
  • The previous outlook covered the full year 2026 only, so there is nothing to compare for this quarter.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second Quarter 2026

AlphAI · Earnings readSEER · Second Quarter 2026 · ended June 30, 2026

Seer Reports Second Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook

↓Weak quarter

Revenue was $3.1 million, a 23% decrease from the corresponding prior-year period, amid macroeconomic headwinds in academic and government funding and longer sales cycles in some commercial accounts. Operating expenses declined 19% and the company reaffirmed full-year revenue guidance of $16 million to $18 million.

Revenue
$3.10M
23% decrease y/y
Product
$2.32M
Gross margin · GAAP
49%
EPS · GAAP
$ (0.31)
Full year 2026 outlook
$16 million to $18 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenue (in thousands)GAAP$3.10M–23% decrease
Product revenue (in thousands)GAAP$2.32M––
Service revenue (in thousands)GAAP679K––
Related party revenue (in thousands)GAAP—––
Other revenue (in thousands)GAAP100K––
Total cost of revenue (in thousands)GAAP$1.60M––
Product cost of revenue (in thousands)GAAP$1.01M––
Service cost of revenue (in thousands)GAAP347K––
Related party cost of revenue (in thousands)GAAP—––
Other cost of revenue (in thousands)GAAP238K––
Gross profit (in thousands)GAAP$1.51M––
Gross marginGAAP49%––
Research and development expense (in thousands)GAAP$8.21M––
Selling, general and administrative expense (in thousands)GAAP10.14M––
Total operating expenses (in thousands)GAAP$18.35M–19% decrease
Stock-based compensationGAAP$1.5M––
Loss from operations (in thousands)GAAP−$16.84M––
Interest income (in thousands)GAAP$2.05M––
Loss on equity method investment (in thousands)GAAP−$2.09M––
Other income (expense) (in thousands)GAAP−$13K––
Total other income (expense) (in thousands)GAAP−$49K––
Loss before provision for income taxes (in thousands)GAAP−$16.89M––
Provision for income taxes (in thousands)GAAP9K––
Net loss (in thousands)GAAP−$16.90M––
Net loss per share attributable to Class A and Class B common stockholders, basic and dilutedGAAP$ (0.31)––
Weighted-average shares used in computing net loss per share attributable to Class A and Class B common stockholders, basic and dilutedGAAP55,164,080––
Comprehensive loss (in thousands)GAAP−$17.17M––
Free cash flow for the six months ended June 30, 2026otherapproximately negative $25.3 million––
Net cash used in operating activities for the six months ended June 30, 2026GAAPapproximately $25.0 million––
Net purchases of property and equipment for the six months ended June 30, 2026GAAPapproximately $265 thousand––

Segments

SegmentRevenueq/qy/y
ProductSales of Proteograph instruments and consumable kits. Product and service revenue was lower as a result of continuing macroeconomic headwinds in academic and government funding and continued elongation of sales cycles in some commercial accounts related to extended customer evaluations.$2.32M––
ServiceProduct and service revenue was lower as a result of continuing macroeconomic headwinds in academic and government funding and continued elongation of sales cycles in some commercial accounts related to extended customer evaluations.679K––
Related partyNo separate driver was reported.— (in thousands)––
OtherNo separate driver was reported.100K––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Full year 2026 outlook

  • Revenue$16 million to $18 million
  • Notegrowth of 3% at the midpoint over full year 2025

Capital returns

  • Repurchased approximately 200,000 Class A common shares under the share repurchase program authorization as of June 30, 2026.

What drove it

  • Revenue declined primarily due to lower product and service revenue resulting from continuing macroeconomic headwinds in academic and government funding.
  • Sales cycles continued to elongate in some commercial accounts because of extended customer evaluations.
  • Operating expenses decreased primarily due to lower employee compensation expenses, including stock-based compensation.
  • The company strengthened its commercial team during the quarter.
  • Korea University collaborators presented preliminary data at ASMS on AI-driven plasma proteomics for multi-cancer screening.
  • Seer initiated enforcement of intellectual property rights against Nanomics Biotechnology Co., Ltd., and the U.S. International Trade Commission opened an investigation.

Concerns

  • Total revenue decreased 23% from the corresponding prior-year period.
  • The company reported a net loss of $16.9 million.
  • Free cash flow for the six months ended June 30, 2026 was approximately negative $25.3 million.
  • Continuing macroeconomic headwinds in academic and government funding and extended customer evaluations affected revenue.
  • Loss on equity method investment was $ (2,088) (in thousands).

What to watch

  • Progress converting scientific leadership and the strengthened commercial team into revenue.
  • Academic and government funding conditions and the duration of commercial customer evaluations.
  • Execution against full-year 2026 revenue guidance of $16 million to $18 million.
  • Developments in the intellectual property enforcement action involving Nanomics Biotechnology Co., Ltd.
  • Cash usage following approximately negative $25.3 million of free cash flow for the six months ended June 30, 2026.

Balance sheet and cash flow

  • Cash, cash equivalents and investments were approximately $209.5 million as of June 30, 2026.
  • Cash and cash equivalents were $ 26,075 (in thousands) as of June 30, 2026, compared to $ 47,285 (in thousands) as of December 31, 2025.
  • Short-term investments were 126,778 (in thousands) as of June 30, 2026, compared to 138,612 (in thousands) as of December 31, 2025.
  • Long-term investments were 56,631 (in thousands) as of June 30, 2026, compared to 54,686 (in thousands) as of December 31, 2025.
  • Total liabilities were 30,958 (in thousands) as of June 30, 2026, compared to 36,776 (in thousands) as of December 31, 2025.
  • Free cash flow for the six months ended June 30, 2026 was approximately negative $25.3 million.

Analysis

Seer reported $3.1 million of second-quarter 2026 revenue, a 23% decrease compared to $4.1 million in the corresponding prior-year period. The company attributed the decline to lower product and service revenue amid continuing macroeconomic headwinds in academic and government funding, as well as elongating sales cycles in some commercial accounts related to extended customer evaluations. Product revenue was $2.3 million, service revenue was $0.7 million, and other revenue was $0.1 million.

Profitability remained negative despite lower costs. Gross profit was $1.5 million and gross margin was 49%. Operating expenses were $18.3 million, including $1.5 million in stock-based compensation, and were down 19% from $22.6 million in the corresponding prior-year period. The company reported a net loss of $16.9 million, compared with $19.4 million in the corresponding prior-year period, while interest income was $2.1 million and loss on equity method investment was $2.1 million.

Capital allocation included the repurchase of approximately 200,000 Class A common shares under the authorization as of June 30, 2026. Cash, cash equivalents and investments totaled approximately $209.5 million at quarter end. Free cash flow, defined as net cash used in operating activities of approximately $25.0 million less net purchases of property and equipment of approximately $265 thousand, was approximately negative $25.3 million for the six months ended June 30, 2026.

Seer reaffirmed full-year 2026 revenue guidance of $16 million to $18 million, representing growth of 3% at the midpoint over full year 2025. The release did not provide prior-quarter operating results, so quarter-over-quarter changes cannot be assessed from the filing. Areas requiring attention are the pace of commercial conversion following the strengthened commercial team, persistence of academic and government funding pressure, extended customer evaluations, cash usage, and execution of the stated revenue outlook.

The company also highlighted customer and collaborator activity around AI-driven plasma proteomics and an independent Nature Genetics study using Proteograph. Management emphasized intellectual property actions against Nanomics Biotechnology Co., Ltd. and the European Patent Office conclusion concerning a patent exclusively licensed by Seer. These developments support the company’s technology and intellectual property positioning, but the reported quarter showed that scientific activity had not yet prevented lower product and service revenue.

Management, verbatim

I’m proud that our technology is enabling the scientific community to do impactful work previously not possible. An important highlight this quarter was the presentation at the ASMS from our customers on how AI-driven proteomics can impact early detection of cancer. During the quarter, we strengthened our commercial team, positioning Seer to better convert scientific leadership into revenue, and we took action to protect our core intellectual property on two continents.

Omid Farokhzad, Chair and Chief Executive Officer

Not in the filing

stated, not guessed
  • Previous quarterly outlook was not provided, so no comparison of actual results with prior guidance is available.
  • Prior-quarter revenue, gross profit, gross margin, operating expenses, operating loss, net loss, EPS, and segment revenue were not reported.
  • Non-GAAP revenue, gross profit, gross margin, operating income, net income, and EPS were not reported.
  • Quarterly operating cash flow and quarterly free cash flow were not reported.
  • Debt was not reported.
  • Dividend information was not reported.
  • Full-year 2026 gross margin, operating expense, tax-rate, EPS, cash-flow, and capital-return guidance were not reported.
  • Prior-year gross margin and percentage changes for individual revenue categories, gross profit, operating loss, net loss, EPS, and cash flow were not reported.
  • CFO commentary was not provided.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about SEER earnings dates

When is Seer's next earnings date?
AlphAI has no date for SEER yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.